Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Aug 1;102(3):550–560. doi: 10.1172/JCI3065

Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection.

C D Ashbaugh 1, H B Warren 1, V J Carey 1, M R Wessels 1
PMCID: PMC508916  PMID: 9691092

Abstract

Human invasive soft-tissue infections caused by group A Streptococcus are associated with significant morbidity and mortality. To investigate the pathogenesis of these serious infections, we characterized the host response to bacterial challenge with an M-type 3 isolate recovered from a patient with necrotizing fasciitis, or with isogenic gene replacement mutants deficient in cysteine protease, hyaluronic acid capsule, or M protein in a murine model of human invasive soft-tissue infection. Animals challenged with the wild-type or cysteine protease-deficient strain developed spreading tissue necrosis at the site of inoculation, became bacteremic, and subsequently died. Histopathologic examination of the necrotic lesion revealed bacteria throughout inflamed subcutaneous tissue. Arterioles and venules in the subcutaneous layer were thrombosed and the overlying tissue was infarcted. In contrast, animals challenged with either an acapsular or M protein-deficient mutant developed a focal area of tissue swelling at the site of inoculation without necrosis or subsequent systemic disease. Histopathologic examination of the soft-tissue lesion demonstrated bacteria confined within a well-formed subcutaneous abscess. We conclude that the group A streptococcal hyaluronic acid capsule and M protein, but not the cysteine protease, are critical for the development of tissue necrosis, secondary bacteremia, and lethal infection in a murine model of human necrotizing fasciitis.

Full Text

The Full Text of this article is available as a PDF (538.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker F. G., Leppard B. J., Seal D. V. Streptococcal necrotising fasciitis: comparison between histological and clinical features. J Clin Pathol. 1987 Mar;40(3):335–341. doi: 10.1136/jcp.40.3.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berge A., Björck L. Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins. J Biol Chem. 1995 Apr 28;270(17):9862–9867. doi: 10.1074/jbc.270.17.9862. [DOI] [PubMed] [Google Scholar]
  3. Burns E. H., Jr, Marciel A. M., Musser J. M. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease. Infect Immun. 1996 Nov;64(11):4744–4750. doi: 10.1128/iai.64.11.4744-4750.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Caparon M. G., Scott J. R. Genetic manipulation of pathogenic streptococci. Methods Enzymol. 1991;204:556–586. doi: 10.1016/0076-6879(91)04028-m. [DOI] [PubMed] [Google Scholar]
  5. Caparon M. G., Stephens D. S., Olsén A., Scott J. R. Role of M protein in adherence of group A streptococci. Infect Immun. 1991 May;59(5):1811–1817. doi: 10.1128/iai.59.5.1811-1817.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chaussee M. S., Liu J., Stevens D. L., Ferretti J. J. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis. 1996 Apr;173(4):901–908. doi: 10.1093/infdis/173.4.901. [DOI] [PubMed] [Google Scholar]
  7. Cleary P. P., Kaplan E. L., Handley J. P., Wlazlo A., Kim M. H., Hauser A. R., Schlievert P. M. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet. 1992 Feb 29;339(8792):518–521. doi: 10.1016/0140-6736(92)90339-5. [DOI] [PubMed] [Google Scholar]
  8. Cleary P. P., Prahbu U., Dale J. B., Wexler D. E., Handley J. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect Immun. 1992 Dec;60(12):5219–5223. doi: 10.1128/iai.60.12.5219-5223.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cone L. A., Woodard D. R., Schlievert P. M., Tomory G. S. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987 Jul 16;317(3):146–149. doi: 10.1056/NEJM198707163170305. [DOI] [PubMed] [Google Scholar]
  10. Crater D. L., Dougherty B. A., van de Rijn I. Molecular characterization of hasC from an operon required for hyaluronic acid synthesis in group A streptococci. Demonstration of UDP-glucose pyrophosphorylase activity. J Biol Chem. 1995 Dec 1;270(48):28676–28680. doi: 10.1074/jbc.270.48.28676. [DOI] [PubMed] [Google Scholar]
  11. Dale J. B., Simmons M., Chiang E. C., Chiang E. Y. Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine. 1996 Jul;14(10):944–948. doi: 10.1016/0264-410x(96)00050-3. [DOI] [PubMed] [Google Scholar]
  12. Davies H. D., McGeer A., Schwartz B., Green K., Cann D., Simor A. E., Low D. E. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med. 1996 Aug 22;335(8):547–554. doi: 10.1056/NEJM199608223350803. [DOI] [PubMed] [Google Scholar]
  13. DeAngelis P. L., Papaconstantinou J., Weigel P. H. Molecular cloning, identification, and sequence of the hyaluronan synthase gene from group A Streptococcus pyogenes. J Biol Chem. 1993 Sep 15;268(26):19181–19184. [PubMed] [Google Scholar]
  14. Dougherty B. A., van de Rijn I. Molecular characterization of hasA from an operon required for hyaluronic acid synthesis in group A streptococci. J Biol Chem. 1994 Jan 7;269(1):169–175. [PubMed] [Google Scholar]
  15. Hauser A. R., Schlievert P. M. Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor. J Bacteriol. 1990 Aug;172(8):4536–4542. doi: 10.1128/jb.172.8.4536-4542.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hollingshead S. K., Simecka J. W., Michalek S. M. Role of M protein in pharyngeal colonization by group A streptococci in rats. Infect Immun. 1993 Jun;61(6):2277–2283. doi: 10.1128/iai.61.6.2277-2283.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Husmann L. K., Yung D. L., Hollingshead S. K., Scott J. R. Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia. Infect Immun. 1997 Apr;65(4):1422–1430. doi: 10.1128/iai.65.4.1422-1430.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ji Y., McLandsborough L., Kondagunta A., Cleary P. P. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun. 1996 Feb;64(2):503–510. doi: 10.1128/iai.64.2.503-510.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. LANCEFIELD R. C. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962 Sep;89:307–313. [PubMed] [Google Scholar]
  20. LANCEFIELD R. C. Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med. 1957 Oct 1;106(4):525–544. doi: 10.1084/jem.106.4.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lukomski S., Burns E. H., Jr, Wyde P. R., Podbielski A., Rurangirwa J., Moore-Poveda D. K., Musser J. M. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun. 1998 Feb;66(2):771–776. doi: 10.1128/iai.66.2.771-776.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lukomski S., Sreevatsan S., Amberg C., Reichardt W., Woischnik M., Podbielski A., Musser J. M. Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains. J Clin Invest. 1997 Jun 1;99(11):2574–2580. doi: 10.1172/JCI119445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Moses A. E., Wessels M. R., Zalcman K., Albertí S., Natanson-Yaron S., Menes T., Hanski E. Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect Immun. 1997 Jan;65(1):64–71. doi: 10.1128/iai.65.1.64-71.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Musser J. M., Kapur V., Kanjilal S., Shah U., Musher D. M., Barg N. L., Johnston K. H., Schlievert P. M., Henrichsen J., Gerlach D. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). J Infect Dis. 1993 Feb;167(2):337–346. doi: 10.1093/infdis/167.2.337. [DOI] [PubMed] [Google Scholar]
  25. Musser J. M., Stockbauer K., Kapur V., Rudgers G. W. Substitution of cysteine 192 in a highly conserved Streptococcus pyogenes extracellular cysteine protease (interleukin 1beta convertase) alters proteolytic activity and ablates zymogen processing. Infect Immun. 1996 Jun;64(6):1913–1917. doi: 10.1128/iai.64.6.1913-1917.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. O'Connor S. P., Cleary P. P. In vivo Streptococcus pyogenes C5a peptidase activity: analysis using transposon- and nitrosoguanidine-induced mutants. J Infect Dis. 1987 Sep;156(3):495–504. doi: 10.1093/infdis/156.3.495. [DOI] [PubMed] [Google Scholar]
  27. Perez-Casal J., Caparon M. G., Scott J. R. Introduction of the emm6 gene into an emm-deleted strain of Streptococcus pyogenes restores its ability to resist phagocytosis. Res Microbiol. 1992 Jul-Aug;143(6):549–558. doi: 10.1016/0923-2508(92)90112-2. [DOI] [PubMed] [Google Scholar]
  28. Perez-Casal J., Price J. A., Maguin E., Scott J. R. An M protein with a single C repeat prevents phagocytosis of Streptococcus pyogenes: use of a temperature-sensitive shuttle vector to deliver homologous sequences to the chromosome of S. pyogenes. Mol Microbiol. 1993 May;8(5):809–819. doi: 10.1111/j.1365-2958.1993.tb01628.x. [DOI] [PubMed] [Google Scholar]
  29. Schrager H. M., Rheinwald J. G., Wessels M. R. Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest. 1996 Nov 1;98(9):1954–1958. doi: 10.1172/JCI118998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Stevens D. L., Tanner M. H., Winship J., Swarts R., Ries K. M., Schlievert P. M., Kaplan E. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989 Jul 6;321(1):1–7. doi: 10.1056/NEJM198907063210101. [DOI] [PubMed] [Google Scholar]
  31. Talkington D. F., Schwartz B., Black C. M., Todd J. K., Elliott J., Breiman R. F., Facklam R. R. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun. 1993 Aug;61(8):3369–3374. doi: 10.1128/iai.61.8.3369-3374.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wang R. F., Kushner S. R. Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli. Gene. 1991 Apr;100:195–199. [PubMed] [Google Scholar]
  33. Wessels M. R., Bronze M. S. Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12238–12242. doi: 10.1073/pnas.91.25.12238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wessels M. R., Goldberg J. B., Moses A. E., DiCesare T. J. Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci. Infect Immun. 1994 Feb;62(2):433–441. doi: 10.1128/iai.62.2.433-441.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wessels M. R., Moses A. E., Goldberg J. B., DiCesare T. J. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8317–8321. doi: 10.1073/pnas.88.19.8317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wexler D. E., Chenoweth D. E., Cleary P. P. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8144–8148. doi: 10.1073/pnas.82.23.8144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wheeler M. C., Roe M. H., Kaplan E. L., Schlievert P. M., Todd J. K. Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. JAMA. 1991 Jul 24;266(4):533–537. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES